CommonSense

Company Overview

Snapshot

Founded in June 1999, CommonSense operates with 51–200 employees. The company was acquired by PEPTONIC Medical AB in October 2021, marking a significant milestone in its trajectory.

Business overview

CommonSense specializes in developing noninvasive diagnostic kits for women's health, focusing on vaginal and urinary tract health. The company's core technology involves built-in sensing capabilities that accurately monitor pH levels, providing early warning systems for conditions such as amniotic fluid leakage and infections. Its products, including AL-SENSE and VS-SENSE, serve global markets within the Health Tech & Life Sciences sector, particularly targeting consumers and healthcare providers with solutions for detection, prevention, and monitoring.

Strategic signal

In October 2021, CommonSense was acquired by PEPTONIC Medical AB. This acquisition signals a strategic consolidation within the women's health diagnostics market, indicating a potential expansion of PEPTONIC Medical AB's product portfolio and market reach through CommonSense's established diagnostic technologies.

Company Intelligence Q&A

What is CommonSense's primary focus?

CommonSense develops noninvasive diagnostic kits designed for women's health, offering products that monitor vaginal and urinary tract health through built-in sensing capabilities.

When was CommonSense founded?

CommonSense was founded in June 1999.

What was a significant corporate event for CommonSense?

In October 2021, CommonSense was acquired by PEPTONIC Medical AB for $375,000, as approved by the court.

What products does CommonSense offer?

CommonSense offers products such as AL-SENSE, which detects amniotic fluid leakage, and VS-SENSE, a swab for differentiating between fungal and bacterial/Trichomoniasis infections.

In which sector does CommonSense primarily operate?

CommonSense operates primarily in the Health Tech & Life Sciences sector, focusing on medical devices and diagnostics.